Inventiva Files 2024 Financial Documents with Regulatory Agencies

Inventiva, a clinical-stage biopharmaceutical company, has announced the filing of its 2024 Universal Registration Document and Annual Report on Form 20-F. These documents, crucial for regulatory compliance, cover the year ending December 31, 2024. Filed with the French Autorité des Marchés Financiers and the U.S. Securities and Exchange Commission, they include detailed financial and management reports.

Inventiva's strategic focus lies in developing therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases. The company's robust scientific team and extensive molecular library support these efforts. Investors and stakeholders can access the comprehensive reports through the company's website and relevant regulatory online platforms.